Johnson & Johnson (JNJ-N) Stock Predictions - Stockchase
WATCH LIST
406
Johnson & Johnson (JNJ-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Johnson & Johnson

JNJ-N

153 watching          
Join the Discussion

Johnson & Johnson (JNJ-N) SAVE Jan, 23, 2019, 3:10 am

128.80 1.89 (1.45%)

About Johnson & Johnson (JNJ-N)

Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886. More at Wikipedia

What the experts are saying about JNJ-N



  • All
  • Filtered
Signal Opinion Expert
BUY
Johnson & Johnson(JNJ-N) 

November 29, 2016

A bond-like proxy for a stock portfolio. One of 3 publicly traded companies that still has an AAA rating credit. They have tremendous amounts of financing capabilities. They pay a nice dividend, and have grown it at a very high rate over the last decade. If they ever wanted to split the company up, they could unlock value in terms of their consumer business, their R&D, and their pharmacy business. This should be a core portion for any portfolio. Doesn’t think this is overly expensive.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A bond-like proxy for a stock portfolio. One of 3 publicly traded companies that still has an AAA rating credit. They have tremendous amounts of financing capabilities. They pay a nice dividend, and have grown it at a very high rate over the last decade. If they ever wanted to split the company up, they could unlock value in terms of their consumer business, their R&D, and their pharmacy business. This should be a core portion for any portfolio. Doesn’t think this is overly expensive.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Petrides

Managing D, Point View Wealth Ma...

Price Price
$112.480
Owned Owned
Unknown

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

November 29, 2016

(A Top Pick Nov 9/15. Up 15.52%.) He sold this in order to buy another stock. This is a great company, but has run up a lot in the last little while. Thinks it will move sideways for the next while. Dividend yield of 2.8%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Nov 9/15. Up 15.52%.) He sold this in order to buy another stock. This is a great company, but has run up a lot in the last little while. Thinks it will move sideways for the next while. Dividend yield of 2.8%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$112.480
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

November 24, 2016

One of the world’s great businesses with their great consumer products business, medical devices and pharma. Shares have risen, so it is no longer a value stock, so he is not going to buy it here. This is a dividend raiser. They ran into a bit of an issue recently. They make Remicade for Crohn’s disease, and there is now a competitor coming out with a bio-similar Remicade. Not cheap enough for him.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the world’s great businesses with their great consumer products business, medical devices and pharma. Shares have risen, so it is no longer a value stock, so he is not going to buy it here. This is a dividend raiser. They ran into a bit of an issue recently. They make Remicade for Crohn’s disease, and there is now a competitor coming out with a bio-similar Remicade. Not cheap enough for him.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Steinberg

President , Lorne Steinberg Weal...

Price Price
$113.070
Owned Owned
No

DON'T BUY
Johnson & Johnson(JNJ-N) 

November 1, 2016

There are 3 parts to their business; pharma, medical devices and consumer products. Medical devices are about 40%, and consumer products are about 20%. Unfortunately, that 60% has had fairly flat growth. The Pharma sector has really been the rock star. Each business would be large enough to stand alone, and you would be better off if the business was split into 3. Decent dividend of about 2.7%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

There are 3 parts to their business; pharma, medical devices and consumer products. Medical devices are about 40%, and consumer products are about 20%. Unfortunately, that 60% has had fairly flat growth. The Pharma sector has really been the rock star. Each business would be large enough to stand alone, and you would be better off if the business was split into 3. Decent dividend of about 2.7%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$115.340
Owned Owned
No

HOLD
Johnson & Johnson(JNJ-N) 

October 25, 2016

A well-run dominant business in many of its key brands from a consumer product standpoint as well as a big healthcare business. Not overly cheap. Has owned this in the past.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A well-run dominant business in many of its key brands from a consumer product standpoint as well as a big healthcare business. Not overly cheap. Has owned this in the past.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Colin Stewart

CEO & Port, JC Clark Investments...

Price Price
$113.960
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

October 25, 2016

(Market Call Minute.) This is a company that has been growing debt, buying back stock and increasing dividends. Ultimately hasn’t increased its revenue in 4 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute.) This is a company that has been growing debt, buying back stock and increasing dividends. Ultimately hasn’t increased its revenue in 4 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John O'Connell,

Chairman a, Davis Rea...

Price Price
$113.960
Owned Owned
Unknown

COMMENT
Johnson & Johnson(JNJ-N) 

October 20, 2016

This would be in the category of a “forever” stock. A very, very consistent and diversified performer. The type of company that supports a constituent of the index that would respond well after the election. He looks for stocks that have higher returns on equity and higher growth rates than this company, but this is one that you could buy, put it away and forget about it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This would be in the category of a “forever” stock. A very, very consistent and diversified performer. The type of company that supports a constituent of the index that would respond well after the election. He looks for stocks that have higher returns on equity and higher growth rates than this company, but this is one that you could buy, put it away and forget about it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$114.870
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

October 19, 2016

One of the big, long term successful companies. The big reason for the stock drop lately is Remicade, its largest drug. Pfizer has something which is going to be priced 5%-10% cheaper. If you are going to be in any of the large cap healthcare stocks, this is the one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the big, long term successful companies. The big reason for the stock drop lately is Remicade, its largest drug. Pfizer has something which is going to be priced 5%-10% cheaper. If you are going to be in any of the large cap healthcare stocks, this is the one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gavin Graham

Trustee, Pointbreak ETFs...

Price Price
$114.590
Owned Owned
Yes

BUY
Johnson & Johnson(JNJ-N) 

October 19, 2016

Drug companies and medical companies have been under a lot of pressure, and a lot of it is politically driven. The US has the highest cost for drugs globally, but also has the most number of pharmaceutical companies. This one is very diversified. His understanding of the California proposition 61 is for regulating drug prices. California kind of leads the nation in terms of propositions. Overall though, this is a fabulous company, and he would use this weakness as an opportunity to Buy.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Drug companies and medical companies have been under a lot of pressure, and a lot of it is politically driven. The US has the highest cost for drugs globally, but also has the most number of pharmaceutical companies. This one is very diversified. His understanding of the California proposition 61 is for regulating drug prices. California kind of leads the nation in terms of propositions. Overall though, this is a fabulous company, and he would use this weakness as an opportunity to Buy.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Stephenson

President , Stephenson & Company...

Price Price
$114.590
Owned Owned
Unknown

DON'T BUY
Johnson & Johnson(JNJ-N) 

October 18, 2016

He would run away.  They are a good offering but the valuation is a little too high.  People gravitate towards what they think is quality.  It is trading at 20 times earnings and have low growth.  He prefers others. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He would run away.  They are a good offering but the valuation is a little too high.  People gravitate towards what they think is quality.  It is trading at 20 times earnings and have low growth.  He prefers others. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$115.410
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

October 17, 2016

One of the few healthcare companies that has held up. There are no catalysts, however.  It is a very solid company that pays a good dividend and has growing earnings. Stick with a winner.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the few healthcare companies that has held up. There are no catalysts, however.  It is a very solid company that pays a good dividend and has growing earnings. Stick with a winner.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ian Shaffer

President, Galliant Advisors...

Price Price
$118.490
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

October 12, 2016

With JNJ-N you are not worried about insurance and health plan payments.  They are continuing to get a higher multiple.  It is probably not a bad way to play it. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

With JNJ-N you are not worried about insurance and health plan payments.  They are continuing to get a higher multiple.  It is probably not a bad way to play it. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$117.970
Owned Owned
Unknown

SELL
Johnson & Johnson(JNJ-N) 

September 27, 2016

Sell? His short answer would be Yes. It is up about 16% year to date, and over the last 52 weeks it is up about 30%. A good quality name. This has benefited from the hunt for yield. The Pharma side is what has really carried this company over the last few years. You can always come back and buy this again.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Sell? His short answer would be Yes. It is up about 16% year to date, and over the last 52 weeks it is up about 30%. A good quality name. This has benefited from the hunt for yield. The Pharma side is what has really carried this company over the last few years. You can always come back and buy this again.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$119.220
Owned Owned
Unknown

TOP PICK
Johnson & Johnson(JNJ-N) 

September 13, 2016

A diversified global healthcare company. About half is pharmaceuticals, and have medical devices as well as consumer brands. In terms of their pharmaceutical division, it has a lot of earnings momentum right now and has been very successful in some of their product launches. Not only are their existing products doing well, but they have a full pipeline. They’ve identified 10 drugs that could potentially be $1 billion drugs over the next 3-5 years. R&D is about 13% of their revenue, so while they do some acquisitions, they are also doing internal development. Dividend yield of 2.72% and has increased the dividend for the last 54 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A diversified global healthcare company. About half is pharmaceuticals, and have medical devices as well as consumer brands. In terms of their pharmaceutical division, it has a lot of earnings momentum right now and has been very successful in some of their product launches. Not only are their existing products doing well, but they have a full pipeline. They’ve identified 10 drugs that could potentially be $1 billion drugs over the next 3-5 years. R&D is about 13% of their revenue, so while they do some acquisitions, they are also doing internal development. Dividend yield of 2.72% and has increased the dividend for the last 54 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$117.610
Owned Owned
Yes

COMMENT
Johnson & Johnson(JNJ-N) 

August 26, 2016

(Market Call Minute.) Has worries about what is happening in the healthcare space in terms of drug pricing, etc. However, the nice thing about this is that it has the consumer products division, so it is a nice diversified health care name.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute.) Has worries about what is happening in the healthcare space in terms of drug pricing, etc. However, the nice thing about this is that it has the consumer products division, so it is a nice diversified health care name.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$119.040
Owned Owned
Unknown

Showing 61 to 75 of 406 entries
Successfully Saved Company
Successfully Saved Company
9+
JOIN THE DISCUSSION
9 comments in the last 7 days